Halling K C, King W, Sokolova I A, Meyer R G, Burkhardt H M, Halling A C, Cheville J C, Sebo T J, Ramakumar S, Stewart C S, Pankratz S, O'Kane D J, Seelig S A, Lieber M M, Jenkins R B
Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
J Urol. 2000 Nov;164(5):1768-75.
We determine the relative sensitivities of cytology and fluorescence in situ hybridization (FISH) for the detection of urothelial carcinoma.
A mixture of fluorescent labeled probes to the centromeres of chromosomes 3, 7 and 17, and band 9p21 (P16/CDKN2A gene) was used to assess urinary cells for chromosomal abnormalities indicative of malignancy. A total of 280 urine specimens from 265 patients, including 150 with a history of urothelial carcinoma and 115 without a history of urothelial carcinoma, were analyzed. FISH analysis was performed without prior knowledge of clinical findings, that is biopsy, cystoscopy and cytology results. A positive result was defined as 5 or more urinary cells with gains of 2 or more chromosomes.
A total of 75 biopsies showed urothelial carcinoma at FISH analysis among the 265 patients. The sensitivity of urine cytology for pTa (36 cases), pTis (18) and pT1-pT4 (15) tumors was 47%, 78% and 60%, respectively, for an overall sensitivity of 58%. The sensitivity of FISH for pTa (37 cases), pTis (17) and pT1-pT4 (19) tumors was 65%, 100% and 95%, respectively, for an overall sensitivity of 81%. FISH was significantly more sensitive than cytology for pTis (p = 0.046), pT1-pT4 (p = 0.025), grade 3 (p = 0.003) and all tumors (p = 0.001). The specificity of cytology and FISH among patients without cystoscopic evidence of urothelial carcinoma and no history of urothelial carcinoma was 98% and 96%, respectively (p = 0.564).
The sensitivity of FISH for the detection of urothelial carcinoma is superior to that of cytology, and the specificity of FISH and cytology for urothelial carcinoma are not significantly different. Further prospective studies are required but FISH has the potential to improve significantly the management of urothelial carcinoma.
我们确定细胞学和荧光原位杂交(FISH)检测尿路上皮癌的相对敏感性。
使用针对3号、7号和17号染色体着丝粒以及9p21带(P16/CDKN2A基因)的荧光标记探针混合物来评估尿路上皮细胞的染色体异常情况,以提示恶性肿瘤。对来自265例患者的总共280份尿液标本进行了分析,其中包括150例有尿路上皮癌病史的患者和115例无尿路上皮癌病史的患者。FISH分析在不了解临床检查结果(即活检、膀胱镜检查和细胞学结果)的情况下进行。阳性结果定义为5个或更多尿路上皮细胞出现2条或更多染色体的增加。
在265例患者中,FISH分析共有75例活检显示为尿路上皮癌。尿细胞学对pTa期(36例)、pTis期(18例)和pT1 - pT4期(15例)肿瘤的敏感性分别为47%、78%和60%,总体敏感性为58%。FISH对pTa期(37例)、pTis期(17例)和pT1 - pT4期(19例)肿瘤的敏感性分别为65%、100%和95%,总体敏感性为81%。对于pTis期(p = 0.046)、pT1 - pT4期(p = 0.025)、3级肿瘤(p = 0.003)和所有肿瘤(p = 0.001),FISH的敏感性显著高于细胞学。在无膀胱镜检查证据显示尿路上皮癌且无尿路上皮癌病史的患者中,细胞学和FISH的特异性分别为98%和96%(p = 0.564)。
FISH检测尿路上皮癌的敏感性优于细胞学,且FISH和细胞学对尿路上皮癌的特异性无显著差异。需要进一步的前瞻性研究,但FISH有可能显著改善尿路上皮癌的管理。